Summary

The 7 major Cushing's syndrome markets reached a value of US$ 385.2 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 831.7 Million by 2034, exhibiting a growth rate (CAGR) of 7.25% during 2024-2034.

The Cushing's syndrome market has been comprehensively analyzed in IMARC's new report titled "Cushing's Syndrome Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Cushing's syndrome is a medical condition that develops when the body is exposed to high levels of cortisol for a prolonged period of time. Several factors, such as the use of oral corticosteroids, the development of a benign tumor on the pituitary gland, or a tumor on the adrenal glands, can contribute to the illness. The signs and symptoms of Cushing's syndrome are wide-ranging and can affect different parts of the body. Some of the common indications include weight gain, fatigue and muscle weakness, high blood pressure, increased thirst, frequent urination, etc. Cushing's syndrome can be diagnosed using a combination of medical history, physical examination, and laboratory investigations. The 24-hour urinary free cortisol test is often used to diagnose the ailment as it measures the amount of cortisol in the urine over a 24-hour period. Cortisol levels can also be measured through blood testing, and a dexamethasone suppression test can assist in identifying whether a tumor or the adrenal glands are responsible for the production of cortisol.

The increasing intake of corticosteroids, either as medication or as part of medical treatment for conditions, such as asthma, rheumatoid arthritis, lupus, etc., is primarily augmenting the global Cushing's syndrome market. In addition to this, the widespread adoption of radiation therapy to reduce the size of a pituitary gland tumor or to treat an adrenal gland tumor that cannot be removed surgically is also bolstering the market growth. Moreover, the emerging popularity of minimally invasive surgical techniques, including laparoscopic adrenalectomy, on account of their several benefits over traditional open surgeries, such as shorter hospital stays, faster recovery period, and less postoperative pain, is acting as a significant growth-inducing factor. Apart from this, the increasing utilization of combination therapy, which involves surgical intervention, medical treatment, and lifestyle changes to effectively manage cortisol levels, is also creating a positive outlook for the market. Furthermore, the introduction of improved delivery methods for medications, including long-acting injections, for enhanced adherence to medication regimens and better control of cortisol levels is expected to drive the global Cushing's syndrome market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the Cushing's syndrome market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for Cushing's syndrome and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Cushing's syndrome market in any manner.

Time Period of the Study

Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034

Countries Covered

United States
Germany
France
United Kingdom
Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario
Historical, current, and future performance of the Cushing's syndrome market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the Cushing's syndrome market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current Cushing's syndrome marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:
Market Insights

How has the Cushing's syndrome market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the Cushing's syndrome market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the Cushing's syndrome market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (​2018-2034​) of Cushing's syndrome across the seven major markets?
What is the number of prevalent cases (​2018-2034​) of Cushing's syndrome by age across the seven major markets?
What is the number of prevalent cases (​2018-2034​) of Cushing's syndrome by gender across the seven major markets?
What is the number of prevalent cases (​2018-2034​) of Cushing's syndrome by type across the seven major markets?
How many patients are diagnosed (​2018-2034​) with Cushing's syndrome across the seven major markets?
What is the size of the Cushing's syndrome patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of Cushing's syndrome?
What will be the growth rate of patients across the seven major markets?

Cushing's Syndrome: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for Cushing's syndrome drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the Cushing's syndrome market?
What are the key regulatory events related to the Cushing's syndrome market?
What is the structure of clinical trial landscape by status related to the Cushing's syndrome market?
What is the structure of clinical trial landscape by phase related to the Cushing's syndrome market?
What is the structure of clinical trial landscape by route of administration related to the Cushing's syndrome market?

ページTOPに戻る

Table of Contents

1 Preface

2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Cushing's Syndrome - Introduction
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence

5 Cushing's Syndrome - Disease Overview
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment

6 Patient Journey

7 Cushing's Syndrome - Epidemiology and Patient Population
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (​2018-2034​)
7.2.4 Epidemiology by Gender (​2018-2034​)
7.2.5 Epidemiology by Type (​2018-2034​)
7.2.6 Diagnosed Cases (​2018-2034​)
7.2.7 Patient Pool/Treated Cases (​2018-2034​)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (​2018-2034​)
7.3.4 Epidemiology by Gender (​2018-2034​)
7.3.5 Epidemiology by Type (​2018-2034​)
7.3.6 Diagnosed Cases (​2018-2034​)
7.3.7 Patient Pool/Treated Cases (​2018-2034​)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (​2018-2034​)
7.4.4 Epidemiology by Gender (​2018-2034​)
7.4.5 Epidemiology by Type (​2018-2034​)
7.4.6 Diagnosed Cases (​2018-2034​)
7.4.7 Patient Pool/Treated Cases (​2018-2034​)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (​2018-2034​)
7.5.4 Epidemiology by Gender (​2018-2034​)
7.5.5 Epidemiology by Type (​2018-2034​)
7.5.6 Diagnosed Cases (​2018-2034​)
7.5.7 Patient Pool/Treated Cases (​2018-2034​)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (​2018-2034​)
7.6.4 Epidemiology by Gender (​2018-2034​)
7.6.5 Epidemiology by Type (​2018-2034​)
7.6.6 Diagnosed Cases (​2018-2034​)
7.6.7 Patient Pool/Treated Cases (​2018-2034​)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (​2018-2034​)
7.7.4 Epidemiology by Gender (​2018-2034​)
7.7.5 Epidemiology by Type (​2018-2034​)
7.7.6 Diagnosed Cases (​2018-2034​)
7.7.7 Patient Pool/Treated Cases (​2018-2034​)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (​2018-2034​)
7.8.4 Epidemiology by Gender (​2018-2034​)
7.8.5 Epidemiology by Type (​2018-2034​)
7.8.6 Diagnosed Cases (​2018-2034​)
7.8.7 Patient Pool/Treated Cases (​2018-2034​)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (​2018-2034​)
7.9.4 Epidemiology by Gender (​2018-2034​)
7.9.5 Epidemiology by Type (​2018-2034​)
7.9.6 Diagnosed Cases (​2018-2034​)
7.9.7 Patient Pool/Treated Cases (​2018-2034​)

8 Cushing's Syndrome - Treatment Algorithm, Guidelines, and Medical Practices
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm

9 Cushing's Syndrome - Unmet Needs

10 Cushing's Syndrome - Key Endpoints of Treatment

11 Cushing's Syndrome - Marketed Products
11.1 List of Cushing's Syndrome Marketed Drugs Across the Top 7 Markets
11.1.1 Isturisa (Osilodrostat) - Recordati
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Recorlev (Levoketoconazole) - Strongbridge Biopharma
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Korlym (Mifepristone) - Corcept Therapeutics
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets

Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.

12 Cushing's Syndrome - Pipeline Drugs
12.1 List of Cushing's Syndrome Pipeline Drugs Across the Top 7 Markets
12.1.1 Relacorilant - Corcept Therapeutics
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 SPI62 - Sparrow Pharmaceuticals
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

13. Cushing's Syndrome - Attribute Analysis of Key Marketed and Pipeline Drugs

14. Cushing's Syndrome – Clinical Trial Landscape
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events

15 Cushing's Syndrome - Market Scenario
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Cushing's Syndrome - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Cushing's Syndrome - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Cushing's Syndrome - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Cushing's Syndrome - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Cushing's Syndrome - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Cushing's Syndrome - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Cushing's Syndrome - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Cushing's Syndrome - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Cushing's Syndrome - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Cushing's Syndrome - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Cushing's Syndrome - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Cushing's Syndrome - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Cushing's Syndrome - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Cushing's Syndrome - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Cushing's Syndrome - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Cushing's Syndrome - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Cushing's Syndrome - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Cushing's Syndrome - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Cushing's Syndrome - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Cushing's Syndrome - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Cushing's Syndrome - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Cushing's Syndrome - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Cushing's Syndrome - Access and Reimbursement Overview

16 Cushing's Syndrome - Recent Events and Inputs From Key Opinion Leaders

17 Cushing's Syndrome Market - SWOT Analysis
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats

18 Cushing's Syndrome Market – Strategic Recommendations

19 Appendix